Skip to Main content Skip to Navigation
Conference papers

Development and in vivo preclinical validation of [18F]FLUSONIM, a highly hydrophilic 18F-labelled 2-nitroimidazole derivative for high performance hypoxia PET imaging

C. Maingueneau 1 A.-E. Lafargue 1 F. Fillesoye 1 J. Toutain 1 S. Valable 1 Myriam Bernaudin 1 S. Guillouet 1 C. Perrio 1 
1 ISTCT - Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales
Document type :
Conference papers
Complete list of metadata
https://hal-normandie-univ.archives-ouvertes.fr/hal-02489356
Contributor : Carole Brunaud Connect in order to contact the contributor
Submitted on : Monday, February 24, 2020 - 1:58:27 PM
Last modification on : Wednesday, March 30, 2022 - 3:23:57 AM

Identifiers

  • HAL Id : hal-02489356, version 1

Collections

CEA | CNRS | COMUE-NORMANDIE | CEA-DRF | UNICAEN | ISTCT | ISTCT-CERVOXY | ISTCT-LDMTEP

Citation

C. Maingueneau, A.-E. Lafargue, F. Fillesoye, J. Toutain, S. Valable, et al.. Development and in vivo preclinical validation of [18F]FLUSONIM, a highly hydrophilic 18F-labelled 2-nitroimidazole derivative for high performance hypoxia PET imaging. 4th Nuclear Technologies for Health Symposium, NTHS2020, Feb 2020, Nantes, France. ⟨hal-02489356⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

54